Global Smoking Cessation Market Revenue Is Expected to Register a CAGR of 17.3% E-cigarettes: An emerging segment in the smoking cessation

Nicotine replacement therapies (NRTs) were the first FDA approved products for smoking cessation treatment. Besides, Buproprion (Zyban) and Varenicline (Chantix) are the two non-nicotine FDA approved products intended for smoking cessation. Electronic nicotine delivery systems (ENDS) are other emerging products aiding in nicotine de-addiction. E-cigarettes can be nicotine-based on non-nicotine based.

Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/134

Rise in depression and anxiety among the population globally is one of the major factors expected to favor market growth for smoking cessation and nicotine de-addiction products. Rising trend among teenagers for taking up smoking products and e-cigarettes due to increasing peer pressure are further favoring growth of the global smoking cessation and nicotine de-addiction products market. The market is estimated to witness considerable revenue traction over the forecast period, due to increasing lifestyle changes and government initiatives promoting smoking cessation and nicotine de-addiction products in Asia and European countries is in turn expected to support growth of the smoking cessation and nicotine de-addiction products market in the near future.

According to Ministry of Health & Family Welfare (MoHFW), Government of India, every March 9, is celebrated as national no-smoking day, which in turn is expected to favor increase in awareness about smoking cessation and nicotine de-addiction products among the population. This is expected to favor growth of the smoking cessation and nicotine de-addiction products market over the forecast period

Intervention for smoking cessation by the population is an urgent need, as the health hazards due to use of tobacco is increasing globally and is especially prevalent in emerging economies. There are different stages of smoking cessation such as pre-contemplation (the initial thought of quitting), contemplation (when a person decides it is time to quit smoking) and so on. Action is when the attempt is made at least for 24 hours and finally maintenance is when a person is smoke-free for over six months. According to The Indian Journal of Chest Diseases & Allied Sciences, published in 2014, the first-line of treatment part of smoking cessation consists of nicotine replacement therapy, bupropion and varinicline, and clonidine and nortriptalin as a second-line of treatment.

Some of the major players are Johnson & Johnson Limited, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Cipla Ltd., Takeda Pharmaceuticals Co. Ltd., NJOY, Inc., Imperial Tobacco Company of India Limited, McNeil AB, and Revolymer Limited

Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/134

Detailed Segmentation:

Global Smoking Cessation and Nicotine De-addiction Products Market, By Product Type:
Nicotine Replacement Therapy
OTC
Nicotine Spray
Nicotine Inhalers
Nicotine Gum
Nicotine Transdermal Patches
Prescription
Nicotine Sublingual Tablets
Nicotine Lozenges
Drugs
Varenicline
Zyban
E-Cigarettes
Modular
Disposable
Rechargeable
Global Smoking Cessation and Nicotine De-addiction Products Market, By Distribution Channel:
Hospital Pharmacies
Online Channel
Retail Pharmacies
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.